Seeking Alpha

Covidien (COV) plans to spin off its pharma business into a standalone public company. At...

Covidien (COV) plans to spin off its pharma business into a standalone public company. At present, the pharma unit accounts for $2B of sales. Post-split, Covidien's medical products business will generate around $9.6B in sales. (PR)
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs